Durvalumab has been approved as a monotherapy in Switzerland for the treatment of adult patients with unresectable small cell lung cancer (LS-SCLC, limited-stage small cell lung cancer) whose disease has not progressed after platinum-based chemoradiotherapy (CRT) [1]. It offers a new treatment option that has been shown to improve the survival of patients with this aggressive form of lung cancer.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Cannabis - medical vs. non-medical use
Interim assessment: the boundaries are fluid
- Case Report
Cutaneous myiasis caused by botfly larvae
- Chronic insomnia, REM sleep instability and emotional dysregulation
Risk factors for anxiety and depression
- Immune sensors
Dysfunctional signaling pathways in cardiomyocytes and their role in heart disease
- Inoperable NSCLC
Efficacy of pembrolizumab in combination with concurrent chemoradiotherapy
- Dementia
Recognize incipient progression and identify countermeasures
- Subtype-specific risks and implications for neurological care
Suicidal tendencies in dementia
- Study report: Hidradenitis suppurativa